Oxurion Finalizes Enrollment in KALAHARI Phase II, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase II, Part B clinical trial for diabetic macular edema. Oxurion’s investigators have successfully over-enrolled the trial with a total of 112 patients.